European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies
A retrospective observational analysis of de-identified data from a multinational medical record review to describe patient characteristics, treatment patterns, and effectiveness of palbociclib + AI as first-line therapy among adult patients with HR+/HER2- advanced breast cancer (ABC) in Europe
Metastatic Breast Cancer
DRUG: Palbociclib + aromatase inhibitor|DRUG: Aromatase inhibitor
Real-world progression free survival, Total time from the treatment line start date to the date of disease progression confirmed by clinician assessment or the date of censoring, as measured in months, Time from treatment line start date to clinician assessed date of disease progression, date of death, or date of censoring
Overall survival, Time from the treatment line start to the date of confirmed death, or the date of censoring, Time from treatment line start date to clinician assessed date of death, or date of censoring|Time to first objective tumor response, Time from the date of treatment line start to the first date of clinician-assessed objective response, or the date of censoring, measured in months, Time from treatment line start date to clinician-assessed first date of objective response or date of censoring
A retrospective observational analysis of de-identified data from a multinational medical record review to describe patient characteristics, treatment patterns, and effectiveness of palbociclib + AI as first-line therapy among adult patients with HR+/HER2- advanced breast cancer (ABC) in Europe